New York Cancer Genomics Research Network Meetings

Computational Cancer Genomics Working Group Evening Lectures

Very Rare Cancer Consortium Tumor Board Meetings

By using state-of-the-art genomic technologies and an unprecedented level of collaboration with the leading research institutions in New York, the NYGC is on the cutting edge of investigation into the origins, diagnosis and evolution of cancer.

Our Genome Center Cancer Group (GCCG), led by Harold Varmus, MD, NYGC and Weill Cornell Medicine, and Charles Sawyers, MD, Memorial Sloan Kettering Cancer Center, is composed of clinicians and cancer researchers from NYGC’s member institutions, including seven NCI-Designated Cancer Centers. The GCCG recently launched Polyethnic-1000, a project to study cancer in New York’s ethnically diverse, underserved patient populations. It is also spearheading the multi-institutional Very Rare Cancer Consortium, a research cohort focused on understanding the genetic causes for rare, understudied cancers.

Our Computational Cancer Genomics Working Group, led by Simon Tavaré, PhD, NYGC and Columbia University, and Sohrab Shah, PhD of Memorial Sloan Kettering Cancer Center, is building collaborations that apply novel statistical approaches and population-level analyses to major cohorts in cancer genomics.

NYGC Core Faculty Members Marcin Imielinski, MD, PhD; Dan Landau, MD, PhD; and Neville Sanjana, PhD, are all also engaged in pioneering cancer research.

Recent Accomplishments:

Mapping Cancer’s Drug Resistance to Design Better Treatment Regimens

Genotyping of Transcriptomes (GoT): New Tool Further Dissects Cancer Complexity

The Mark Foundation for Cancer Research Awards a $1M grant to the New York Genome Center (NYGC) to support the Polyethnic-1000 Project

NYGC Core Faculty Member Dan Landau, MD, PhD, Receives 2018 NIH New Innovator Award for Cancer Research

NYGC Core Faculty Member Neville Sanjana Receives 2018 AAAS Martin and Rose Wachtel Cancer Research Award